SwanBio Therapeutics
3675 Market Street
Philadelphia
PA
19104
United States
Website: https://www.swanbiotx.com/
Email: info@swanbiotx.com
21 articles about SwanBio Therapeutics
-
SwanBio Unveils Research in Next Generation CNS Capsids at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
5/18/2023
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, presented preliminary data from primate studies of AAV capsids that outperform the commonly used AAV9 capsid.
-
SwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women
5/10/2023
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women.
-
SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy
12/15/2022
SwanBio Therapeutics today announced the initiation of its PROPEL clinical trial.
-
SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments
6/27/2022
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today presented details about the company’s ongoing natural history study of adrenomyeloneuropathy (AMN) at the 8th Congress of the European Academy of Neurology (EAN) in Vienna.
-
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
-
SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions
5/18/2022
SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus -based therapies for the treatment of devastating, inherited neurological conditions, announced the completion of a $56 million Series B financing round, led by founding investors Syncona Limited and Mass General Brigham Ventures.
-
Additional Preclinical Data Supports Clinical Advancement of First AAV-Based Gene Therapy for Adrenomyeloneuropathy
5/17/2022
SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions, today presented additional details from studies of SBT101.
-
SwanBio Therapeutics to Present Preclinical Data on Lead Candidate at American Society of Gene & Cell Therapy
4/19/2022
SwanBio Therapeutics to Present Preclinical Data on Lead Candidate at American Society of Gene & Cell Therapy 2022 Annual Meeting in Washington, DC May 16-19.
-
Updated Preclinical Data Support Potential of First AAV-Based Gene Therapy as a Treatment for Adrenomyeloneuropathy
4/5/2022
SwanBio Therapeutics today presented updated data from studies of the company’s lead candidate in non-human primates (NHPs) and rodent models.
-
FDA Grants Orphan Drug Designation to SBT101, the First Investigational AAV-Based Gene Therapy for Adrenomyeloneuropathy (AMN)
3/15/2022
SwanBio Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead candidate, SBT101.
-
SwanBio Therapeutics to Present New Preclinical Data Showcasing AAV-Based Gene Therapy Candidate for Adrenomyeloneuropathy at American Academy of Neurology Annual Meeting
3/4/2022
SwanBio Therapeutics today announced that the company will present data supporting the clinical advancement of its lead candidate, SBT101, at the American Academy of Neurology (AAN) 2022 Annual Meeting.
-
FDA Grants Fast Track Designation to SBT101, the First Investigational AAV-Based Gene Therapy for Patients With Adrenomyeloneuropathy (AMN)
2/16/2022
SwanBio Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead candidate, SBT101, for the treatment of adrenomyeloneuropathy (AMN).
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
SwanBio Therapeutics Announces FDA Investigational New Drug Clearance for First AAV-Based Gene Therapy for the Treatment of Adrenomyeloneuropathy
1/25/2022
SwanBio Therapeutics today announced that its Investigational New Drug (IND) application for its lead candidate, SBT101, for the treatment of adrenomyeloneuropathy (AMN) was cleared by the U.S. Food and Drug Administration (FDA).
-
Shares of Mustang Bio have fallen more than 13% in premarket trading after announcing the FDA had placed a hold on the company’s Investigational New Drug application for its bubble boy gene therapy.
-
SwanBio Therapeutics Announces New Preclinical Data Demonstrating Proof of Principle for SBT101 Gene therapy as a Potential Treatment of Adrenomyeloneuropathy
10/19/2021
SwanBio Therapeutics, a gene therapy company focused on developing treatments for patients with genetically defined neurological conditions, announced new preclinical efficacy and safety data supporting the potential of the company’s lead program, SBT101, as a disease-modifying treatment for adrenomyeloneuropathy.
-
SwanBio Therapeutics Announces First Patient Enrolled in Natural History Study to Evaluate Patients with Adrenomyeloneuropathy
6/29/2021
SwanBio Therapeutics today announced the initiation of the CYGNET study with the enrollment of the first two participants.
-
SwanBio Therapeutics Appoints Marita James, CPA, as Chief Financial Officer
3/23/2021
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced that Marita James, CPA, has been appointed as the company’s Chief Financial Officer.
-
SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders
11/20/2020
SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointments of Patricia “Patty” Allen, former Chief Financial Officer of Zafgen, Inc.; Danny Bar-Zohar, M.D., Global Head of Development at Merck KGaA; and Alex Hamilton, Ph.D., Partner at Syncona, to the company’s Board of Directors
-
SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer
6/1/2020
SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neurological diseases, today announced the appointment of Steven Zelenkofske , D.O., M.S. as chief medical officer (CMO). Dr. Zelenkofske brings more than 20